Skip to main content

Arthritis, Psoriatic

10
Pipeline Programs
12
Companies
23
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
5
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
686%
Small Molecule
114%
+ 9 programs with unclassified modality

On Market (3)

Approved therapies currently available

Pfizer
XELJANZ XRApproved
tofacitinib
Pfizer
oral2016
586M Part D
Pfizer
XELJANZApproved
tofacitinib
Pfizer
oral2020
280M Part D
Pfizer
TOFACITINIBApproved
tofacitinib
Pfizer
oral

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
1
TofacitinibPhase 3Small Molecule5 trials
Active Trials
NCT05195814Completed141Est. Oct 2023
NCT04424303Completed152Est. Dec 2025
NCT04485325Completed92Est. Mar 2024
+2 more trials
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
99Tc methylene diphosphonatePhase 41 trial
Active Trials
NCT05000086Completed20Est. Jul 2021
MSD
MSDIreland - Ballydine
2 programs
1
Infliximab + methotrexatePhase 31 trial
RemicadeN/A1 trial
Active Trials
NCT00725296Completed178Est. Jul 2010
NCT00367237Completed115Est. Mar 2008
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
Infliximab + methotrexatePhase 3
RemicadeN/A
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Infliximab + methotrexatePhase 3
Sandoz
SandozAustria - Kundl
1 program
1
SecukinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02294227Completed341Est. Dec 2017
Enlivex Therapeutics
Enlivex TherapeuticsIsrael - Ness Ziona
1 program
1
AllocetraPhase 11 trial
Active Trials
NCT06522035Terminated5Est. Apr 2026
MoonLake Immunotherapeutics
4 programs
SonelokimabPHASE_2Monoclonal Antibody1 trial
SonelokimabPHASE_3Monoclonal Antibody1 trial
SonelokimabPHASE_3Monoclonal Antibody1 trial
SonelokimabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT05640245Completed207Est. Jan 2024
NCT07223138Enrolling By Invitation1,560Est. Feb 2028
NCT06641076Active Not Recruiting960Est. Feb 2027
+1 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
BI 730357PHASE_21 trial
risankizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04680676Withdrawn0Est. Sep 2023
NCT02719171Completed185Est. Aug 2017
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
CZP 200 mg Q2WPHASE_31 trial
Active Trials
NCT01087788Completed409Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
PfizerTofacitinib
UNION therapeutics99Tc methylene diphosphonate
PfizerTofacitinib
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
SandozSecukinumab
PfizerTofacitinib
UCB PharmaCZP 200 mg Q2W
MSDInfliximab + methotrexate
MoonLake ImmunotherapeuticsSonelokimab
Boehringer IngelheimBI 730357
Boehringer Ingelheimrisankizumab
Enlivex TherapeuticsAllocetra
PfizerTofacitinib

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 21,192 patients across 23 trials

Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

Start: Nov 2019Est. completion: Mar 202492 patients
Phase 4Completed
NCT05000086UNION therapeutics99Tc methylene diphosphonate

A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis

Start: Jun 2019Est. completion: Jul 202120 patients
Phase 4Completed

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Start: Mar 2014Est. completion: Jul 20204,372 patients
Phase 4Completed

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Start: Nov 2025Est. completion: Feb 20281,560 patients
Phase 3Enrolling By Invitation

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Start: Oct 2024Est. completion: Jan 2027600 patients
Phase 3Recruiting

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Start: Oct 2024Est. completion: Feb 2027960 patients
Phase 3Active Not Recruiting

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

Start: May 2015Est. completion: Dec 2017341 patients
Phase 3Completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Start: Feb 2014Est. completion: May 2019686 patients
Phase 3Completed
NCT01087788UCB PharmaCZP 200 mg Q2W

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Start: Mar 2010Est. completion: Aug 2015409 patients
Phase 3Completed
NCT00367237MSDInfliximab + methotrexate

Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)

Start: May 2006Est. completion: Mar 2008115 patients
Phase 3Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Start: Dec 2022Est. completion: Jan 2024207 patients
Phase 2Completed

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Start: May 2022Est. completion: Sep 20230
Phase 2Withdrawn

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Start: Apr 2016Est. completion: Aug 2017185 patients
Phase 2Completed

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Start: Aug 2024Est. completion: Apr 20265 patients
Phase 1Terminated

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

Start: Oct 2019Est. completion: Dec 201912 patients
Phase 1Completed

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Start: May 2019Est. completion: Jun 20215 patients
Phase 1Completed

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

Start: Nov 2021Est. completion: Oct 2023141 patients
N/ACompleted

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

Start: Dec 2020Est. completion: Dec 2025152 patients
N/ACompleted

Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)

Start: Apr 2019Est. completion: Apr 20191,057 patients
N/ACompleted

Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

Start: Nov 2018Est. completion: Jan 2024103 patients
N/ATerminated

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Start: Jan 2017Est. completion: Dec 202624 patients
N/AEnrolling By Invitation

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

Start: Jul 2013Est. completion: Aug 20219,968 patients
N/ACompleted

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Start: Dec 2004Est. completion: Jul 2010178 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 21,192 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.